Search Results

By Charlotte Bath  / Tuesday, June 3, 2014 11:43 PM

ASCO 2014: Adding Lapatinib to Adjuvant Trastuzumab Does Not Improve Outcomes in Early-Stage HER2-Positive Breast Cancer

A large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation), found no statistically significant differences in 4-year disease-free survival among women with early HER2-positive breast cancer who received adjuvant treatment that combined the HER2-targeted drugs...